Lysogene Forms Solid Financial Team With Two Senior Appointments
Berndt Modig joins as Senior Financial Advisor and Sarah Ankri joins as Finance Director
Paris, France—November 9, 2015—Lysogene, a leading, clinical-stage biotechnology company committed to the development and commercialization of breakthrough treatments for severe orphan pathologies affecting the central nervous system, has appointed two executives to its financial team.
Berndt A. Modig joins the firm as its Senior Financial Advisor. In his role with the company, Mr. Modig will be the most senior Finance staff member. Sarah Ankri joins the team as Finance Director.
Mr. Modig has spent more than 30 years in finance, with a large portion of that time being spent in healthcare finance. His most recent roles include Chief Financial Officer at Prosensa (Nasdaq: RNA), which was acquired by BioMarin, and Chief Financial Officer at Jerini AG, which was acquired by Shire.
His extensive international background also includes experience with the successful execution of complex financial strategies, operations management and audit committee roles. Mr. Modig is currently serving on the boards of Axovant Sciences Ltd. (NYSE:AXON), Auris Medical AG (Nasdaq: EARS) and Affimed N.V. (Nasdaq: AFMD), and he will maintain those positions as he assumes his new role at Lysogene.
Ms. Ankri is a graduate of the National Institute of Agronomy (INA P-G/AgroParisTech) and has a Masters in Economy and Management. She acquired her financial knowledge related to Bio-and Medtech companies, including fundraising (Europe & USA) during the 6 years she spent at Ernst & Young working on legal audit and advisory/acquisition missions in the healthcare sector. Prior to joining Lysogene, she was CFO at Theraclion and successfully led the company’s IPO in 2014.
Ms. Karen Aiach, Founder and CEO of Lysogene, said: “We are thrilled to welcome Berndt and Sarah to Lysogene. Both have proven experience and tangible success in their previous roles, and I have no doubt that their financial leadership will help steer the firm in the right direction as we press ahead with the development of our gene therapy programs.”
Mr. Modig stated: “It’s great to be supporting a company as dynamic as Lysogene at such an exciting time in its development, and I’m looking forward to being a part of all that is to come.”
Ms. Ankri stated: “The advancements that Lysogene has brought to the field of gene therapy are inspiring. I am excited to join such an experienced team and to support Lysogene’s further growth”.
For more information about Lysogene, please visit www.lysogene.com.
Help employers find you! Check out all the jobs and post your resume. About Lysogene: Lysogene is a clinical stage biotechnology company and a pioneer in the basic research and clinical development of gene therapy for CNS disorders. Lysogene is committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high unmet medical needs. Lysogene’s team translated its rAAVrh10 lead product, for mucopolysaccharidoses IIIA (MPS IIIA) also known as Sanfilippo syndrome type A, from bench to bedside in less than five years. For more information, please visit www.lysogene.com.
Paris, France—November 9, 2015—Lysogene, a leading, clinical-stage biotechnology company committed to the development and commercialization of breakthrough treatments for severe orphan pathologies affecting the central nervous system, has appointed two executives to its financial team.
Berndt A. Modig joins the firm as its Senior Financial Advisor. In his role with the company, Mr. Modig will be the most senior Finance staff member. Sarah Ankri joins the team as Finance Director.
Mr. Modig has spent more than 30 years in finance, with a large portion of that time being spent in healthcare finance. His most recent roles include Chief Financial Officer at Prosensa (Nasdaq: RNA), which was acquired by BioMarin, and Chief Financial Officer at Jerini AG, which was acquired by Shire.
His extensive international background also includes experience with the successful execution of complex financial strategies, operations management and audit committee roles. Mr. Modig is currently serving on the boards of Axovant Sciences Ltd. (NYSE:AXON), Auris Medical AG (Nasdaq: EARS) and Affimed N.V. (Nasdaq: AFMD), and he will maintain those positions as he assumes his new role at Lysogene.
Ms. Ankri is a graduate of the National Institute of Agronomy (INA P-G/AgroParisTech) and has a Masters in Economy and Management. She acquired her financial knowledge related to Bio-and Medtech companies, including fundraising (Europe & USA) during the 6 years she spent at Ernst & Young working on legal audit and advisory/acquisition missions in the healthcare sector. Prior to joining Lysogene, she was CFO at Theraclion and successfully led the company’s IPO in 2014.
Ms. Karen Aiach, Founder and CEO of Lysogene, said: “We are thrilled to welcome Berndt and Sarah to Lysogene. Both have proven experience and tangible success in their previous roles, and I have no doubt that their financial leadership will help steer the firm in the right direction as we press ahead with the development of our gene therapy programs.”
Mr. Modig stated: “It’s great to be supporting a company as dynamic as Lysogene at such an exciting time in its development, and I’m looking forward to being a part of all that is to come.”
Ms. Ankri stated: “The advancements that Lysogene has brought to the field of gene therapy are inspiring. I am excited to join such an experienced team and to support Lysogene’s further growth”.
For more information about Lysogene, please visit www.lysogene.com.
Help employers find you! Check out all the jobs and post your resume. About Lysogene: Lysogene is a clinical stage biotechnology company and a pioneer in the basic research and clinical development of gene therapy for CNS disorders. Lysogene is committed to the development and commercialization of innovative therapies for patients affected with rare disorders and high unmet medical needs. Lysogene’s team translated its rAAVrh10 lead product, for mucopolysaccharidoses IIIA (MPS IIIA) also known as Sanfilippo syndrome type A, from bench to bedside in less than five years. For more information, please visit www.lysogene.com.